PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma

doi:10.1038/s41392-021-00522-6

	PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma
	Xie, Qin 1,4; Chi, Shuaishuai 1,5; Fang, Yanfen 1; Sun, Yiming 1; Meng, Linghua 1; Ding, Jian 1,2,3; Chen, Yi 1,5
刊名	SIGNAL TRANSDUCTION AND TARGETED THERAPY
	2021-03-31
卷号	6 期号:1 页码:3
ISSN号	2095-9907
DOI	10.1038/s41392-021-00522-6
通讯作者	Ding, Jian(jding@simm.ac.cn) ; Chen, Yi(ychen@simm.ac.cn)
资助项目	Strategic Priority Research Program of the Chinese Academy of Science[XDA12020101] ; Strategic Priority Research Program of the Chinese Academy of Science[XDA12050101] ; National Natural Science Foundation of China[81521005]
WOS研究方向	Biochemistry & Molecular Biology ; Cell Biology
语种	英语
出版者	SPRINGERNATURE
WOS记录号	WOS:000636231100001
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/295443]
专题	中国科学院上海药物研究所
通讯作者	Ding, Jian; Chen, Yi
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, Shanghai, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China 3.Shanghai HaiHe Pharmaceut Co Ltd, Shanghai, Peoples R China 4.Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Xie, Qin,Chi, Shuaishuai,Fang, Yanfen,et al. PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2021,6(1):3.
APA	Xie, Qin.,Chi, Shuaishuai.,Fang, Yanfen.,Sun, Yiming.,Meng, Linghua.,...&Chen, Yi.(2021).PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma.SIGNAL TRANSDUCTION AND TARGETED THERAPY,6(1),3.
MLA	Xie, Qin,et al."PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma".SIGNAL TRANSDUCTION AND TARGETED THERAPY 6.1(2021):3.